Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 27, 2022

Sciwind, SynerK to develop novel therapeutics for liver and metabolic diseases

Clinical-stage biopharmaceutical firm Sciwind Biosciences has signed a research partnership agreement with RNAi therapeutics company SynerK for the joint development of novel therapeutics to treat liver and metabolic diseases.

Continue
The companies will discover and develop novel siRNA therapeutics. Credit: günter from Pixabay.
September 26, 2022

NICE recommends MSD’s pembrolizumab to treat melanoma

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Credit: Julio C. Valencia / commons.wikimedia.org.
September 23, 2022

China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer

AstraZeneca R&D, China. Credit: AstraZeneca.

Contracts

August 25, 2022

Bavarian Nordic and PAHO sign agreement for monkeypox vaccines

The agreement will facilitate access to Bavarian Nordic’s monkeypox vaccines in Latin America and the Caribbean. Credit: NIAID / Flickr <a href=(Creative Commons)">

Bavarian Nordic to supply additional monkeypox vaccine doses to US

SK Biopharmaceuticals signs licensing agreement with Eurofarma for cenobamate

WuXi XDC, AbTis sign MoU to develop ADC products

Deals

Deals August 18, 2022

Bristol Myers Squibb acquires Turning Point for $4.1bn

Pharmaceutical Business Review

CAMP4 Therapeutics closes $100m round to advance lead regRNA programmes

Regeneron completes acquisition of Sanofi’s stake in Libtayo

Boehringer Ingelheim signs option to acquire Trutino Biosciences

Popular

  1. Lilly’s Retevmo receives FDA approval to treat solid tumours
  2. Alnylam receives EU marketing authorisation for hATTR amyloidosis therapy
  3. NETRIS Pharma, Orano and CLB partner to develop new radio-conjugates
  4. FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine
  5. Kite’ Yescarta gets CHMP positive opinion to treat large B-cell lymphoma

PRESS RELEASES

GxP Refresher Training ICH Q8, Q9 and Q10
GxP Refresher Training ICH Q8, Q9 and Q10
RWS at RAPS Convergence 2022
RWS at RAPS Convergence 2022
Molnár-Institute Exhibits at ISC 2022 in Budapest, 18–22 September 2022
Molnár-Institute Exhibits at ISC 2022 in Budapest, 18–22 September 2022
Gerresheimer and Stevanato Group Announce Collaboration on the Development of an Innovative Ready-to-Use Vial Platform for the Pharmaceutical Industry
Gerresheimer and Stevanato Group Announce Collaboration on the Development of an Innovative Ready-to-Use Vial Platform for the Pharmaceutical Industry
In Autumn 2022, CBDepot Returns to Live Pharma Shows
In Autumn 2022, CBDepot Returns to Live Pharma Shows

Suppliers

Whitepapers

How to Manage Analytical Methods Across All Stages of their Lifecycle Using One Chromatographic Modelling Tool
How to Manage Analytical Methods Across All Stages of their Lifecycle Using One Chromatographic Modelling Tool
Flexible Choices in Design Space Modelling to Support Smooth Pharma Production
Flexible Choices in Design Space Modelling to Support Smooth Pharma Production
Computer-Assisted Method Development for Small and Large Molecules
Computer-Assisted Method Development for Small and Large Molecules